188
Participants
Start Date
December 31, 2001
Primary Completion Date
April 30, 2006
Study Completion Date
July 31, 2006
NBI-6024
0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
Children's Hospital of Eastern Ontario, Ottawa
Center Hospitalier Universitaire de Sherbrooke, Sherbrooke
Centre de recherche clinique de Laval, Laval
University Hospital and School of Medicine, Olomouc
Faculty Hospital Motol, Prague
Helsinki University Hospital, Helsinki
Hôpital Debrousse, Lyon
Hôpital St Vincent de Paul, Paris
Diabetes Center for Children and Adolescents, Hanover
Institut für Diabetesforschung, München
New Groote Schuur Hospital, Cape Town
Parklands Medical Center, Durban
Center for Diabetes and Endocrinology, Johannesburg
Donald Gordon Medical Center, Johannesburg
Medigate Medical Center, KwaZulu Natal
Helderberg Diabetic Clinic and Practice, Somerset West
Hospital Clinic de Barcelona, Barcelona
Hospital de Cruces, Cruces-Baracado
Hospital Materno-Infantil, Málaga
University Hospital Virgen del Rocío, Seville
Maternal and Child Health Services 2, Dundee
Lead Sponsor
Neurocrine Biosciences
INDUSTRY